Results 11 to 20 of about 474,753 (298)

Effect of fruit smoothie supplementation on psychological distress among people with substance use disorders receiving opioid agonist therapy: protocol for a randomised controlled trial (FruktBAR)

BMC Nutrition, 2022
Background People with substance use disorders generally have unhealthy diets, including limited intake of fruit and vegetables. Evidence shows substantial health benefits from increasing fruit and vegetable consumption on various indicators and possibly
Lars T. Fadnes, Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Jørn Henrik Vold, Maria Olsvold, Marianne Cook Pierron, Siv-Elin Leirvåg Carlsen, Rune Blomhoff, Torgeir Gilje Lid, for the ATLAS4LAR Study Group   +10 more
doaj   +1 more source

Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR)

Trials, 2022
Background About 85% of patients receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Although smoke-related pulmonary diseases are significant contributors to morbidity and mortality, few smoking cessation interventions are ...
Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Jan Tore Daltveit, Jørn Henrik Vold, Torgeir Gilje Lid, Tesfaye Madebo, Lars Thore Fadnes, for the ATLAS4LAR Study Group   +7 more
doaj   +1 more source

Vitamin D status and associations with substance use patterns among people with severe substance use disorders in Western Norway

Scientific Reports, 2022
Chronic and harmful substance use is associated with a cluster of harms to health, including micronutrient deficiencies. Maintaining adequate levels of vitamin D is important for musculoskeletal and other aspects of health.
Mitra Bemanian, Ranadip Chowdhury, Krister Stokke, Christer Frode Aas, Kjell Arne Johansson, Jørn Henrik Vold, Lars Thore Fadnes   +6 more
doaj   +1 more source

Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2)

BMC Psychiatry, 2020
Background Available evidence suggests that adjunctive treatment with immunomodulatory medications may be effective in the treatment of major depressive disorder (MDD).
Muhammad Ishrat Husain, Clare Cullen, Madeha Umer, Andre F. Carvalho, Stefan Kloiber, Jeffrey H. Meyer, Abigail Ortiz, Yuliya Knyahnytska, M. Omair Husain, Justine Giddens, Breno S. Diniz, Wei Wang, Allan H. Young, Benoit H. Mulsant, Zafiris J. Daskalakis   +14 more
doaj   +1 more source

Collision of the COVID-19 and Addiction Epidemics

Annals of Internal Medicine, 2020
People with substance use disorder may be especially susceptible to COVID-19, and compromised lung function from COVID-19 could also put at risk those who have opioid use disorder and methamphetamine use disorder.
N. Volkow
semanticscholar   +1 more source

Equine-assisted services for individuals with substance use disorders: a scoping review

Substance Abuse Treatment, Prevention, and Policy, 2022
The implementation of equine-assisted services (EAS) during treatment for psychological disorders has been frequently documented; however, little is known about the effect of EAS on outcomes for populations with substance use disorder (SUD).
Liam Diaz, Mirinda Ann Gormley, Ashley Coleman, Abby Sepanski, Heather Corley, Angelica Perez, Alain H. Litwin   +6 more
doaj   +1 more source

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Translational Psychiatry, 2021
Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15–20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease.
Sri Mahavir Agarwal, Roshni Panda, Kenya A. Costa-Dookhan, Nicole E. MacKenzie, Quinn Casuccio Treen, Fernando Caravaggio, Eyesha Hashim, General Leung, Anish Kirpalani, Kelly Matheson, Araba F. Chintoh, Caroline K. Kramer, Aristotle N. Voineskos, Ariel Graff-Guerrero, Gary J. Remington, Margaret K. Hahn   +15 more
doaj   +1 more source

Estimation of Behavioral Addiction Prevalence During COVID-19 Pandemic: A Systematic Review and Meta-analysis

Current Addiction Report, 2022
The COVID-19 pandemic changed people’s lifestyles and such changed lifestyles included the potential of increasing addictive behaviors. The present systematic review and meta-analysis aimed to estimate the prevalence of different behavioral addictions (i.
Zainab Alimoradi, Aida Lotfi, Chung-Ying Lin, M. Griffiths, A. Pakpour   +4 more
semanticscholar   +1 more source

Test characteristics of shorter versions of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for brief screening for problematic substance use in a population sample from Israel

Substance Abuse Treatment, Prevention, and Policy, 2023
Background Substance use is a leading cause of preventable morbidity and mortality worldwide. Population-wide screening for problematic substance use in primary health care may mitigate the serious health and socio-economic consequences of such use, but ...
Dvora Shmulewitz, Roi Eliashar, Maor Daniel Levitin, Shaul Lev-Ran   +3 more
doaj   +1 more source

Identifying contexts and mechanisms in multiple behavior change interventions affecting smoking cessation success: a rapid realist review

BMC Public Health, 2020
Background Smoking continues to be a leading cause of preventable chronic disease-related morbidity and mortality, excess healthcare expenditure, and lost work productivity.
Nadia Minian, Tricia Corrin, Mathangee Lingam, Wayne K. deRuiter, Terri Rodak, Valerie H. Taylor, Heather Manson, Rosa Dragonetti, Laurie Zawertailo, Osnat C. Melamed, Margaret Hahn, Peter Selby   +11 more
doaj   +1 more source